EC
TEVA icon

EntryPoint Capital’s Teva Pharmaceuticals TEVA Stock Holding History

EntryPoint Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,102
Closed -$29.7K – 1605
2024
Q1 		$29.7K Buy
+2,102
New +$26.5K 0.03% 960

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's TEVA Position: Q2 2024 in Review

EntryPoint Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 2,102 shares — an estimated $29.7K sold.

EntryPoint Capital first reported a position in TEVA in Q1 2024 and held it in 1 quarter. The position peaked at $29.7K in Q1 2024. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • EntryPoint Capital reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 2,102 Teva Pharmaceuticals shares in Q2 2024, an estimated $29.7K.
  • EntryPoint Capital first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • EntryPoint Capital's Teva Pharmaceuticals position peaked at $29.7K in Q1 2024.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.